Youn H Kim
Academic Appointments
- Professor - Med Center Line, Dermatology
- Member, Stanford Cancer Institute
- Professor - Med Center Line (By courtesy), Medicine - Oncology
Key Documents
Contact Information
-
Clinical Offices
Stanford Cancer Center 875 Blake Wilbur Drive Clinic A Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 721-2521Cutaneous Oncology 900 Blake Wilbur Drive, MC 5356 Office W1010 Stanford, CA 94305 Tel Work (650) 725-3292 Fax (650) 725-6937
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Cutaneous (Dermatologic) Oncology
- Cutaneous Lymphoma
- Cutaneous Lymphoma - Dermatology
- Dermatology
- Mycosis Fungoides
- Mycosis Fungoides - Dermatology
Administrative Appointments
- Director, Multi-disciplinary Cutaneous Lymphoma Program, Stanford University Medical Center (2004 - present)
- Director, Residency Program, Department of Dermatology, Stanford University Medical Center (2004 - present)
- Medical Director, Photopheresis Unit, Stanford University Medical Center (2004 - present)
Honors and Awards
- Alwin C. Rambar-James B.D. Mark Award for Excellence in Patient Care, Stanford University School of Medicine (2001)
- Distinguished Service Award, Department of Dermatology, Stanford University School of Medicine (1995)
- The Best Doctors in America: Pacific Region, Woodward/White, Inc (1996-)
Professional Education
| Board Certification: | Dermatology, American Board of Dermatology (1989) |
| Internship: | Kaiser - San Francisco (1985) |
| Medical Education: | Stanford University School of Medicine CA (1984) |
| Doctor of Medicine: | Stanford University, Medicine (1984) |
| Bachelor of Arts: | Wellesley College, Chemistry (1980) |
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
Clinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.
Clinical Trials
- Recruiting Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
- Recruiting A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
- Recruiting Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
- Recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
- Not Recruiting Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Publications
- In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood. 2012; (2): 355-63
- Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol. 2012; (24): e221-5
- Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood. 2012; (16): 3288-97
- Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 2011; (4): e651-7
- Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010; (29): 4485-91
- In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010; (28): 4324-32
Help